Fritextsökning
Innehållstyper
-
Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”
It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or wheth...
-
The dock that “thinks” for itself
The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...
-
Introduction of ZEISS Imaging Systems for Super-Resolution
Webinar recording about the ZEISS Lattice SIM technology.
-
Första svenska patienten behandlad med Carvykti – ”Gått som planerat”
För första gången har en svensk patient behandlats med Carvykti, en CAR-T-cellterapi mot blodcancerformen multipelt myelom. Bakom behandlingen ligger flera års ...
-
Life science trends 2025 – Part 1 obesity drugs
More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...
-
The Top 10 Challenges Facing Laboratories Today
Navigating the Laboratory Automation Landscape
-
BioArctic moves forward with its candidate for Parkinson’s
BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.
-
Mastering Urine Microscopy: Techniques for Accurate Disease Detection
Live Webinar on September 25, 2024.
-
Specific proposals and targets top the universities’ desired priorities
What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Kar...
-
Tio life science-projekt får miljonanslag – ny utlysning öppnar
En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.
-
Saving lives worldwide with low-cost molecular diagnostics
High throughput testing for many upper respiratory tract pathogens thanks to automation technology
-
Large study: The benefits and risks of obesity medications
Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...
-
AstraZeneca to use American AI platform for cancer trials
In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.
-
New moves around Nykode's management – withdrawal of resignations
Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.
-
MSD discontinues development of cancer drugs after trial failures
MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.
-
Non-destructive testing and assembly control
Assess complete assembly.
-
Vaccine skeptic David Geier to lead study on link to autism
The American government is to launch a study on whether vaccines cause autism – and has appointed a well-known vaccine skeptic to lead the analysis.
-
She is CSL Behring's new Nordic General Manager
Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.
-
Moderna develops mRNA vaccine against norovirus
A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...
-
Security flaw in Swedish breast cancer screening software – woman passed away
A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 o...
-
ZEISS continues to drive digital era forward in ophthalmology
2 million digitally planned cataract cases in the U.S. alone.
-
Cost-efficient development of laboratory devices
8 ways to optimise development costs and speed up processes
-
New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"
For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...
-
Samuel Lagercrantz: “Companies that do this successfully will take the lead”
The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that r...
BREAKING